Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours
1999
Hepatitis B Virus and Chemotherapy in Cancer Patients
Sample size: 1008
publication
Evidence: moderate
Author Information
Author(s): Alexopoulos C G, Vaslamatzis M, Hatzidimitriou G
Primary Institution: Department of Medical Oncology and Blood Transfusion Unit, Evangelismos Hospital
Hypothesis
What is the prevalence of hepatitis B virus positivity and how does the HBV profile evolve during chemotherapy in cancer patients?
Conclusion
Reactivation of HBV infection during chemotherapy occurs in 14% of patients, and the disappearance of HBs antigenaemia is not common or permanent.
Supporting Evidence
- 54 (5.3%) of patients were HBsAg carriers.
- 443 (44%) had at least one HBV marker positive.
- 374 (41%) of chemotherapy receivers were HBcAb+ve.
Takeaway
In cancer patients getting chemotherapy, some have hepatitis B, and it can come back during treatment.
Methodology
Serum HBV markers and liver biochemistry were determined in cancer patients admitted to the unit.
Participant Demographics
Cancer patients receiving chemotherapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website